~~<i id='69627EFB21'><strike id='69627EFB21'><tt id='69627EFB21'><pre id='69627EFB21'></pre></tt></strike></i>~~

Home» explore» focus

focus

author：explore 2025-10-06 17:11:35 Page View：8682

Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks.

“Oh, crap,” Secrist said to herself.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Diversity in clinical trials starts with building trust, experts say
Next article： Virginia high school admissions case could be legal follow

explore

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

1:19Ademonstratorrunsonthethirdnightofprotestssparkedbythefatalpoliceshootingofa17-year-olddriverint

More tobacco lobbyists active in statehouses

NathanHoward/GettyImagesWASHINGTON—Aroundthecountry,statehousesfromHarrisburg,Pa.,toTallahassee,Fla.

Novavax promises a turnaround & Lilly roils the obesity market

SammyKimballforSTATCanNovavaxfinallygetitright?What’sa“triple-G”drug?AndisNovoNordisklosingground?We

Diversity in clinical trials starts with building trust, experts say

SilasBuchanan,CEOofOurHealthyCommunity,speaksonapanelaboutdemocratizingclinicaltrialsattheMilkenInst